Marvin White retires as Aptevo CEO; COO Jeff Lamothe named successor effective April 1, 2026

Aptevo Therapeutics Inc.

White to become Executive Chair; Lamothe promoted from COO to President and CEO and appointed to Board.
John Niederhuber transitions from Chairman to Lead Independent Director; Board expands to seven directors.
Lamothe receives $650K base salary, 60% bonus target, and a one-time $150K cash promotional award.
Severance Plan modified to align Executive Chair benefits with CEO-level benefits; EVP tier removed.
Company notes cash runway into 2029, $60M equity line, and clinical progress with mipletamig Phase 1b.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.